Cerebrolysin: experimental and theoretical vindication of clinical effectiveness
Abstract
Corporative data by company EBEWE Pharma
Cerebrolysin – neurotrophic and neuroprotecive pharmaceutical drug – is well known to practitioners, and was used in clinical practice for several decades. Despite its clinical effectiveness, shown by many clinical investigations, mechanisms of its action remained unknown. The investigations of the last years of 20th century have clarified obscure thus far mechanisms, cumulative evidence of which underlies the neuroprotective and neurotrophic actions of cerebrolysin. The results of recent experimental investigations brought out clearly the reasons for assertion about cerebrolysin effectiveness in brain injury, both with acute and chronic course.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2004 EBEWE Pharma
This work is licensed under a Creative Commons Attribution 4.0 International License.
Ukrainian Neurosurgical Journal abides by the CREATIVE COMMONS copyright rights and permissions for open access journals.
Authors, who are published in this Journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the Journal under the terms of Creative Commons Attribution License, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this Journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form of which it has been published by the Journal (for example, to upload the work to the online storage of the Journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this Journal is included.
